These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 2179614

  • 1. Management of hyperlipidemia of kidney disease.
    Grundy SM.
    Kidney Int; 1990 Mar; 37(3):847-53. PubMed ID: 2179614
    [No Abstract] [Full Text] [Related]

  • 2. Drug therapy in dyslipidemia.
    Grundy SM.
    Scand J Clin Lab Invest Suppl; 1990 Mar; 199():63-72. PubMed ID: 2191420
    [No Abstract] [Full Text] [Related]

  • 3. Indications and outcome of treatment of hyperlipidemia in pediatric allograft recipients.
    Silverstein DM.
    Pediatr Transplant; 2003 Feb; 7(1):7-10. PubMed ID: 12581321
    [No Abstract] [Full Text] [Related]

  • 4. Cholesterol-lowering drugs as cardioprotective agents.
    Grundy SM.
    Am J Cardiol; 1992 Dec 21; 70(21):27I-32I. PubMed ID: 1471602
    [Abstract] [Full Text] [Related]

  • 5. [Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome].
    Wakasugi H, Yoshimoto M, Aoki M, Osawa R, Futami T, Ono T, Muso E, Inui K.
    Nihon Jinzo Gakkai Shi; 2001 Oct 21; 43(7):595-9. PubMed ID: 11725557
    [Abstract] [Full Text] [Related]

  • 6. Choice of cholesterol-lowering drugs.
    Med Lett Drugs Ther; 1993 Mar 05; 35(891):19-22. PubMed ID: 8433674
    [No Abstract] [Full Text] [Related]

  • 7. Mechanisms and treatment of dyslipidemia of renal diseases.
    Toto RD, Vega GL, Grundy SM.
    Curr Opin Nephrol Hypertens; 1993 Sep 05; 2(5):784-90. PubMed ID: 7922219
    [Abstract] [Full Text] [Related]

  • 8. Effect of probucol on hyperlipidemia in patients with nephrotic syndrome.
    Iida H, Izumino K, Asaka M, Fujita M, Nishino A, Sasayama S.
    Nephron; 1987 Sep 05; 47(4):280-3. PubMed ID: 3696330
    [Abstract] [Full Text] [Related]

  • 9. [Nicotinic acid and the derivative].
    Ogaki S, Matsushima T.
    Nihon Rinsho; 2001 Mar 05; 59 Suppl 3():637-41. PubMed ID: 11347146
    [No Abstract] [Full Text] [Related]

  • 10. [Therapeutic management].
    Vanzetto G, Fouque D, Moulin B, Halimi S, Kessler M, Bayle F.
    Nephrologie; 2000 Mar 05; 21(7):383-92. PubMed ID: 11200619
    [No Abstract] [Full Text] [Related]

  • 11. Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study.
    Querfeld U, Kohl B, Fiehn W, Minor T, Michalk D, Schärer K, Müller-Wiefel DE.
    Pediatr Nephrol; 1999 Jan 05; 13(1):7-12. PubMed ID: 10100282
    [Abstract] [Full Text] [Related]

  • 12. [Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia].
    Martínez-Castelao A.
    Med Clin (Barc); 1995 Nov 25; 105(18):719. PubMed ID: 8538262
    [No Abstract] [Full Text] [Related]

  • 13. [Treatments for dyslipidemia associated with kidney disease].
    Hirano T, Yoshino G.
    Nihon Rinsho; 2001 Mar 25; 59 Suppl 3():748-52. PubMed ID: 11347167
    [No Abstract] [Full Text] [Related]

  • 14. Drug therapy of hyperlipidemia.
    Prihoda JS, Illingworth DR.
    Curr Probl Cardiol; 1992 Sep 25; 17(9):545-605. PubMed ID: 1446461
    [No Abstract] [Full Text] [Related]

  • 15. [Hyperlipidemia in kidney diseases].
    Saito T.
    Nihon Rinsho; 2007 Jul 28; 65 Suppl 7():407-11. PubMed ID: 17824062
    [No Abstract] [Full Text] [Related]

  • 16. [Dyslipidemias in renal diseases: pathogenesis and treatment].
    Cuevas A, Maíz A, Arteaga A.
    Rev Med Chil; 1998 Mar 28; 126(3):315-21. PubMed ID: 9674303
    [Abstract] [Full Text] [Related]

  • 17. [Evaluation of the efficacy of statin therapy in dyslipidemic diseases such as combined hypercholesterolemia IIA and hyperlipidemia].
    Liguori E, Sarcinella R.
    Minerva Cardioangiol; 1998 Sep 28; 46(9):317-8. PubMed ID: 10021861
    [No Abstract] [Full Text] [Related]

  • 18. Severe hyperlipidemia due to multiple factors in a child with nephrotic syndrome.
    Ongkingco JR, Mann WA, Ruley EJ, Gregg RE.
    Child Nephrol Urol; 1991 Sep 28; 11(2):107-10. PubMed ID: 1756519
    [Abstract] [Full Text] [Related]

  • 19. Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in various forms of dyslipidemia.
    Grundy SM, Vega GL, Garg A.
    Am J Cardiol; 1990 Sep 18; 66(8):31B-38B. PubMed ID: 2206034
    [Abstract] [Full Text] [Related]

  • 20. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D, Shabpar A, Böhmig G, Schmaldienst S, Hörl WH, Watschinger B.
    Wien Klin Wochenschr; 2000 Apr 21; 112(8):358-61. PubMed ID: 10849941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.